MX2024005777A - Isoxazolidinas como inhibidores de ripk1 y uso de estas. - Google Patents
Isoxazolidinas como inhibidores de ripk1 y uso de estas.Info
- Publication number
- MX2024005777A MX2024005777A MX2024005777A MX2024005777A MX2024005777A MX 2024005777 A MX2024005777 A MX 2024005777A MX 2024005777 A MX2024005777 A MX 2024005777A MX 2024005777 A MX2024005777 A MX 2024005777A MX 2024005777 A MX2024005777 A MX 2024005777A
- Authority
- MX
- Mexico
- Prior art keywords
- isoxazolidines
- inhibitors
- ripk1
- ripk1 inhibitors
- kinase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000002546 isoxazolidines Chemical class 0.000 title abstract 2
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract 2
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación se refiere a isoxazolidinas y su uso como inhibidores de la proteína cinasa 1 que interacciona con receptores, por ejemplo, en el tratamiento de enfermedades y trastornos mediados por la cinasa RIP 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21315242 | 2021-11-11 | ||
| PCT/EP2022/081226 WO2023083847A1 (en) | 2021-11-11 | 2022-11-09 | Isoxazolidines as ripk1 inhibitors and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005777A true MX2024005777A (es) | 2024-07-19 |
Family
ID=78916777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005777A MX2024005777A (es) | 2021-11-11 | 2022-11-09 | Isoxazolidinas como inhibidores de ripk1 y uso de estas. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11897876B2 (es) |
| EP (1) | EP4430037B1 (es) |
| JP (1) | JP2024544533A (es) |
| KR (1) | KR20240099451A (es) |
| CN (1) | CN118510775A (es) |
| AR (1) | AR127640A1 (es) |
| AU (1) | AU2022388696A1 (es) |
| CA (1) | CA3237975A1 (es) |
| CO (1) | CO2024007013A2 (es) |
| IL (1) | IL312739A (es) |
| MX (1) | MX2024005777A (es) |
| TW (1) | TW202340182A (es) |
| WO (1) | WO2023083847A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024544533A (ja) * | 2021-11-11 | 2024-12-03 | ジェンザイム・コーポレーション | Ｒｉｐｋ１阻害剤としてのイソオキサゾリジン及びその使用 |
| WO2025137210A1 (en) | 2023-12-21 | 2025-06-26 | Genzyme Corporation | Crystalline form of an isoxazolidine derivative |
| EP4652998A1 (en) * | 2024-05-21 | 2025-11-26 | Technische Universität München | Treatment of receptor-interacting protein kinase 1- mediated disease with eclitasertib |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI648273B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類（三） |
| CN106573006A (zh) | 2014-08-21 | 2017-04-19 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为药物的rip1激酶抑制剂杂环酰胺 |
| JP6683712B2 (ja) | 2014-12-24 | 2020-04-22 | ナショナル・インスティチュート・オブ・バイオロジカル・サイエンシズ，ベイジン | ネクローシス阻害薬 |
| TWI730959B (zh) | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| WO2017069279A1 (ja) | 2015-10-23 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
| US10709692B2 (en) | 2015-12-04 | 2020-07-14 | Denali Therapeutics Inc. | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) |
| KR102808827B1 (ko) | 2016-02-05 | 2025-05-19 | 데날리 테라퓨틱스 인크. | 수용체-상호작용 단백질 키나제 1의 억제제 |
| TW201831464A (zh) | 2016-11-18 | 2018-09-01 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| PE20241932A1 (es) | 2017-05-17 | 2024-09-24 | Denali Therapeutics Inc | Inhibidores de quinasa y usos de los mismos |
| US11072617B2 (en) | 2017-10-31 | 2021-07-27 | Genentech, Inc. | Bicyclic sulfones and sulfoxides and methods of use thereof |
| BR112020013247A2 (pt) | 2017-12-29 | 2020-12-01 | Glaxosmithkline Intellectual Property Development Limited | amidas heterocíclicas como inibidores de quinase |
| EP3781571B1 (en) | 2018-04-20 | 2024-01-17 | F. Hoffmann-La Roche AG | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| CN110872285A (zh) | 2018-08-31 | 2020-03-10 | 宁波文达医药科技有限公司 | 作为受体相互作用蛋白1(rip1)激酶抑制剂的杂环化合物 |
| KR20200087922A (ko) | 2019-01-11 | 2020-07-22 | 보로노이바이오 주식회사 | (3-페닐이속사졸리딘-2-일)(피페리딘-4-일)메타논 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 |
| JP2024544533A (ja) * | 2021-11-11 | 2024-12-03 | ジェンザイム・コーポレーション | Ｒｉｐｋ１阻害剤としてのイソオキサゾリジン及びその使用 |
-
2022
- 2022-11-09 JP JP2024527549A patent/JP2024544533A/ja active Pending
- 2022-11-09 US US17/983,883 patent/US11897876B2/en active Active
- 2022-11-09 CA CA3237975A patent/CA3237975A1/en active Pending
- 2022-11-09 CN CN202280087723.2A patent/CN118510775A/zh active Pending
- 2022-11-09 EP EP22817150.0A patent/EP4430037B1/en active Active
- 2022-11-09 MX MX2024005777A patent/MX2024005777A/es unknown
- 2022-11-09 AU AU2022388696A patent/AU2022388696A1/en active Pending
- 2022-11-09 IL IL312739A patent/IL312739A/en unknown
- 2022-11-09 WO PCT/EP2022/081226 patent/WO2023083847A1/en not_active Ceased
- 2022-11-09 KR KR1020247019088A patent/KR20240099451A/ko active Pending
- 2022-11-09 TW TW111142740A patent/TW202340182A/zh unknown
- 2022-11-10 AR ARP220103098A patent/AR127640A1/es unknown
-
2023
- 2023-08-08 US US18/231,628 patent/US20240109882A1/en not_active Abandoned
-
2024
- 2024-05-31 CO CONC2024/0007013A patent/CO2024007013A2/es unknown
- 2024-09-27 US US18/900,128 patent/US20250122186A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL312739A (en) | 2024-07-01 |
| EP4430037A1 (en) | 2024-09-18 |
| EP4430037B1 (en) | 2025-10-29 |
| JP2024544533A (ja) | 2024-12-03 |
| EP4430037C0 (en) | 2025-10-29 |
| CA3237975A1 (en) | 2023-05-19 |
| WO2023083847A1 (en) | 2023-05-19 |
| CO2024007013A2 (es) | 2024-07-18 |
| KR20240099451A (ko) | 2024-06-28 |
| AU2022388696A1 (en) | 2024-06-27 |
| US11897876B2 (en) | 2024-02-13 |
| US20250122186A1 (en) | 2025-04-17 |
| TW202340182A (zh) | 2023-10-16 |
| US20240109882A1 (en) | 2024-04-04 |
| US20230203027A1 (en) | 2023-06-29 |
| AR127640A1 (es) | 2024-02-14 |
| CN118510775A (zh) | 2024-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024007013A2 (es) | Isoxazolidinas como inhibidores de ripk1 y uso de estas | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| CR20190063A (es) | 3-metil pirazinas 2,5-disustituídas y 3-metil pirazinas 2,5,6-trisustituídas como inhibidores alostéricos de shp2 | |
| CO2017011851A2 (es) | Compuestos novedosos | |
| ECSP18073726A (es) | Inhibidores del enlace proteína-proteína de wdr5 | |
| MX2022001299A (es) | Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas. | |
| CO2018009275A2 (es) | Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub) | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
| MX2018001706A (es) | Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1). | |
| CO2018001840A2 (es) | Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5 | |
| MX2023004920A (es) | Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6). | |
| CL2021002878A1 (es) | Tratamiento y prevención de enfermedades metabólicas | |
| AR113803A1 (es) | Compuesto de pirimidina como inhibidor de jak quinasas | |
| BR112018014590A2 (pt) | formulações/composições compreendendo um inibidor de btk | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| CO2021007402A2 (es) | Constructos de suministro para transcitosis y métodos relacionados | |
| UY35344A (es) | Oestra-1,3,5(10),16-tetraeno-3-carboxamidas | |
| MX2024004119A (es) | Composiciones y metodos para el tratamiento de enfermedades de repeticion cag | |
| CO2021013171A2 (es) | Compuestos y composiciones como moduladores de la señalización de tlr | |
| CO2023005057A2 (es) | Compuestos y composiciones como moduladores de señalización tlr | |
| DOP2017000244A (es) | Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap) | |
| DOP2019000221A (es) | Derivados de pirazol como inhibidores de bromodominio | |
| CL2021000580A1 (es) | Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares. | |
| MX2024002913A (es) | Anticuerpos anti-siglec-6 y metodos de uso de los mismos. |